Trending Now
Four Red-Hot Investing Themes for 2021 (RIOT, BLNK, TONJ, GRWG)
We have turned the page to a new year, filled with fresh hopes and fears. But, so far, it feels a little...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
EyePoint Pharmaceutical Inc. (NASDAQ:EYPT) Reports Revenue Of $15.7 Million In Q3...
EyePoint Pharmaceutical Inc. (NASDAQ:EYPT) has announced Q3 2020 financial results and provided its recent corporate development updates.
DEXYCU and YUTIQ net sales of $5.8 million
The...
MAKE IT MODERN
LATEST REVIEWS
Evofem Biosciences Inc.’s (NASDAQ: EVFM) Phexxi Access Expanded Under New Guidelines...
Evofem Biosciences Inc. (NASDAQ: EVFM) has applauded the United States Department of Labour and Health Resources and Services Administration (HRSA) for issuing updated contraceptive...
MAKE IT MODERN
PERFORMANCE TRAINING
Precigen Inc (NASDAQ: PGEN) Announces Definitive Agreement For The Sale Of Tran Ova Genetics...
Precigen Inc (NASDAQ: PGEN) has announced a definitive agreement to sell its wholly-owned animal reproductive technology subsidiary Trans Ova Genetics L.C. to URUS for...
Nabriva Therapeutics plc (NASDAQ: NBRV) Receives marketing Approval for IV and oral Lefamulin Formulations...
Nabriva Therapeutics plc (NASDAQ: NBRV) has announced that The Chinese Centre for Drug Evaluation has accepted its partner Sumitomo Pharmaceuticals' new drug application for...
Market looks primed for Quadruple Witching
The market is set to open relatively flat this morning and is expected to move lower due to a lot of choppiness today, since...
Precision Biosciences Inc. (NASDAQ:DITL) Reports Positive Preliminary Results From PBCAR0911 Study
Precision Biosciences Inc. (NASDAQ:DITL) has announced positive preliminary clinical results from the Phase 1/2a PBCAR0191 study. PBCAR0191 is Precision Biosciences' off-the-shelf, allogeneic CAR T...
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP)’s Phase 3 DETERMINE Clinical Study Of Lenabasum Unable...
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) posted topline results of Phase 2 DETERMINE Clinical trial of Lenabasum in patients with heterogeneous and rare ADD...
MAKE IT MODERN
